SK Biopharmaceuticals Co., Ltd.
326030
Classificação em ações
#4037
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Preço da ação
$51.65
Valor de mercado
$4.05B
Variação (1 dia)
0.27%
Variação (1 ano)
-30.95%
País
KR
Negociar SK Biopharmaceuticals Co., Ltd. (326030)
Categoria
Healthcare
Lucros da SK Biopharmaceuticals Co., Ltd. (326030)
Lucros em Jun 2026 TTM: $199.99M
De acordo com os últimos relatórios financeiros da SK Biopharmaceuticals Co., Ltd., os ganhos atuais da empresa são de $199.99M. Em 2024, a empresa teve ganhos de $49.38M, um aumento em relação a aos ganhos de 2023, que foram de $-33.88M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da SK Biopharmaceuticals Co., Ltd. de 2011 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $199.99M | 91.48% |
| 2025 | $104.44M | 111.52% |
| 2024 | $49.38M | -245.75% |
| 2023 | $-33.88M | -69.99% |
| 2022 | $-112.90M | -288.31% |
| 2021 | $59.95M | -127.13% |
| 2020 | $-220.98M | 202.16% |
| 2019 | $-73.13M | -40.83% |
| 2018 | $-123.61M | 36.08% |
| 2017 | $-90.84M | 260.75% |
| 2016 | $-25.18M | 14.75% |
| 2015 | $-21.94M | -33.74% |
| 2014 | $-33.12M | -18.07% |
| 2013 | $-40.42M | 43.63% |
| 2012 | $-28.14M | 57.64% |
| 2011 | $-17.85M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | 2,537.63% |
US
|
|
| $-3.09B | -1,643.61% |
US
|
|
| $-4.02B | -2,108.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 875.39% |
NL
|
